IPHA
Innate Pharma S.A. ADS
stockNASDAQADR
innate pharma s.a. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immune system. innate pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. the company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs. innate pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of natural killer cell biology. this innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including astrazeneca, bristol-myers squibb, novo nordisk a/s and sanofi. innate pharma
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.70 | 2026-09-28 | -9.12% | -0.055 |
| 1M | 2.08 | 2026-09-04 | -25.72% | -0.839 |
| 3M | 1.87 | 2026-07-06 | -17.38% | 0.039 |
| 6M | 1.39 | 2026-04-06 | +11.15% | 1.773 |
| 1Y | 2.06 | 2025-10-03 | -24.82% | 1.366 |
| 2Y | 2.17 | 2024-10-04 | -28.75% | — |
| 5Y | 5.98 | 2021-10-04 | -74.16% | 0.127 |
Innate Pharma S.A. ADS (NASDAQ:IPHA) stock price today is $1.55, and today's volume is 92,739. IPHA is down 2.830% today. The 30 day average volume is 44,683. IPHA market cap is $172.58M with 111.70M shares outstanding.